Provided by Tiger Trade Technology Pte. Ltd.

Avis Budget

146.88
+0.27000.18%
Post-market: 146.880.00000.00%19:40 EDT
Volume:260.36K
Turnover:38.39M
Market Cap:5.19B
PE:-8.19
High:149.85
Open:146.39
Low:146.39
Close:146.61
52wk High:847.70
52wk Low:85.96
Shares:35.32M
Float Shares:14.85M
Volume Ratio:1.03
T/O Rate:1.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.9408
EPS(LYR):-25.2557
ROE:5800.00%
ROA:2.70%
PB:-1.53
PE(LYR):-5.82

Loading ...

Avis Budget price target raised to $155 from $140 at JPMorgan

TIPRANKS
·
Jun 09

Avis Budget Group Inc : JP Morgan Raises Target Price to $155 From $140

THOMSON REUTERS
·
Jun 09

Avis Budget Group Inc. : Barclays Raises to Equal-Weight From Underweight

THOMSON REUTERS
·
Jun 09

U.S. RESEARCH ROUNDUP- Apple, Lennar, Toll Brothers

Reuters
·
Jun 09

Imugene Wins FDA Fast Track for Off-the-Shelf CAR T in CLL/SLL and MZL

TIPRANKS
·
Jun 09

Avis Budget Shares Rise After Upgrade From Barclays

MT Newswires Live
·
Jun 09

Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says

MT Newswires Live
·
Jun 08

Avis Budget Group Raised to Equal-Weight From Underweight by Barclays

Dow Jones
·
Jun 08

Movement Alert|Avis Budget Group Rises 5.21% in Regular Trading, Upgraded by Barclays to Equal Weight

Market Focus
·
Jun 08

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

GlobeNewswire
·
Jun 08

Barclays Upgrades Avis Budget Group to Equalweight From Underweight, Adjusts PT to $160 From $140

MT Newswires Live
·
Jun 08

A Look At Cencora (COR) Valuation After 2026 Guidance Update And New CAR T Distribution Deal

Simply Wall St.
·
Jun 08

What Is the Impact of Rupiah Weakening on Banks?

Tempo
·
Jun 05

Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline

TIPRANKS
·
Jun 05

3 ASX Dividend Stocks To Consider With Up To 7.5% Yield

Simply Wall St.
·
Jun 05

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

GlobeNewswire
·
Jun 04

Sami Corwin Initiates Buy on Kyverna (KYTX) on Differentiated miv-cel Efficacy and Advancing BLA for First Autoimmune CAR T Approval

TIPRANKS
·
Jun 04

Legend Biotech ADRs Climb on Preliminary Study Results for Non-Hodgkin Lymphoma Treatment

Dow Jones
·
Jun 03

Legend Biotech presents preliminary clinical data for LB2501 at EHA Congress

TIPRANKS
·
Jun 02

CSPC Pharma's Pioneering mRNA-LNP Dual-Target CAR-T Cell Therapy Gains Clinical Trial Approval in China

Stock News
·
Jun 02